Cellestis, Qiagen deal

Qiagen will acquire Australian diagnostics company Cellestis for A$3.55 per share or A$341 million ($354.4 million) in cash. The price is an 18% premium to Cellestis' close of A$3 on April 1, before the deal was announced. The deal is subject to Cellestis shareholder approval at a meeting slated for June. ...